CSSD Capital
80 Raffles Place, #43-01, UOB Plaza, Singapore, 048624
Overview
SooChow CSSD Capital Markets is an investment bank focusing on emerging growth companies across Asia, providing a full suite of investment banking services, including corporate finance, mergers and acquisitions advisory, equity capital markets, institutional equities sales and trading and equities research. SCCM is an organisation that has built a reputation for excellence based on the expertise and track record of professional team members, the strength of execution capabilities and being aligned with their clients to create or enhance value for them.
- Total investments
- 2
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Advice
- Asset Management
- Banking
- Financial Services
Investment portfolio
- Qi Biodesign
Participated · Series A · Dec 2024
Qi Biodesign builds and commercializes a proprietary SEEDIT™ research platform that includes novel RNA‑guided nucleases, base editors, plant prime editors, and PrimeRoot™ editors for precise large DNA insertions and multiplex trait engineering. Its tools enable multiplex gene editing, fine‑tuning of gene expression, high‑throughput trait discovery, and acceleration of superior trait development for crops and synthetic biology applications. The company has achieved regulatory milestones, including two biosafety certificates from the China Ministry of Agriculture and Rural Affairs for high oleic acid soybean and powdery mildew‑resistant wheat, and an exemption from the U.S. Department of Agriculture for its high oleic acid soybean. Qi Biodesign is advancing additional traits—yield, herbicide tolerance, and quality improvements—through regulatory pipelines. The company plans to use new funding to enhance R&D, advance SEEDIT™, support product development, and build commercialization platforms to speed transition from research to market. Founded by genome‑editing scientists and industry executives, Qi Biodesign positions its platform to address food security and sustainable agriculture challenges.
- Ractigen Therapeutics
Participated · Series A · Jan 2022
Ractigen Therapeutics, founded in 2017 by RNAa pioneers Dr. Long-Cheng Li, Dr. Robert Place and Dr. Moorim Kang, develops therapies that use small activating RNAs (saRNA) to up‑regulate targeted endogenous genes. The company has built an SCAD delivery system designed to improve biodistribution in extrahepatic tissues and claims a pipeline of first‑in‑class candidate medicines for unmet genetic disorders. Ractigen is a late‑stage preclinical company focused on advancing multiple programs toward clinical development. It is scaling oligonucleotide manufacturing capabilities to support progression of programs. The company closed an additional Series A+ financing to fund these development and manufacturing plans. All information here is sourced from the provided article.
Team
No current team members are available.